Mr. Neil Flanzraich
Chairman of the Board and Co-Founder
Mr. Flanzraich is the Chairman and Co-Founder of AgoneX Biopharmaceuticals, Inc. He is also the Executive Chairman of Cantex Pharmaceuticals, Inc., a biotech company developing novel therapies for cancer. He is also the Executive Chairman of the Board of Directors of Alzheon, Inc., a biotech company developing drugs for Alzheimer’s. He is a Director of Chipotle Mexican Grill, Inc. (CMG:NYSE), a restaurant chain, and is also a member of the Board of Directors of Atrium European Real Estate Limited (VSE/Euronext:ATRS), an owner/manager of shopping centers in Central and Eastern Europe. Mr. Flanzraich served as the Vice Chairman and President of Ivax Corporation, an international pharmaceutical company, which was sold to Teva in 2006 for an enterprise value of $10 Billion. He was also the Chairman of North American Vaccine, Inc., and has served as a director for many pharma and biotech corporations. He has also consulted for private equity firms and institutional investors on pharmaceutical transactions and investments. Mr. Flanzraich graduated from Harvard College (magna cum laude, Phi Beta Kappa) and from Harvard Law School (magna cum laude).
Mr. Wayne P. Yetter
Board of Directors Member
Wayne Yetter had a 30-year career in the pharmaceutical industry and held executive positions at Pfizer, Merck, Astra-Merck (now AstraZeneca) and Novartis. His roles included President and Chief Executive Officer of Novartis Pharmaceuticals Corporation, the US division of Novartis AG, Vice President, Marketing Operations (global) and Vice President, Far East and Pacific at Merck and founding Chief Executive Officer of Astra-Merck. He also served as Chief Operating Officer of IMS Health, a market research data company from 1999 until 2000, when he became Chairman and Chief Executive Officer of Synavant, Inc. (a Nasdaq listed spin-out of IMS) that was acquired by Dendrite International in 2003. Mr. Yetter then served as Chief Executive Officer of Verispan LLC, a Joint venture of McKesson and Quintiles and leading provider of healthcare information and marketing services to the pharmaceutical industry, from 2005 to 2008. Verispanwas acquired by SDI Health and later merged into IMS. Most recently, Mr. Yetter was Chairman of the Board of NuPathe Inc. that was acquired by TEVA in early 2014. He serves as a director of InfuSystem Holdings, Inc.(INFU), and Special Diversified Opportunities Inc. (SDOI) a shell company remaining after the sale of assets of Strategic Diagnostics. (SDIX). Previously he served as Chairman of Noven Pharmaceuticals, Chairman of Transkaryotic Therapies, and Lead Independent Director of Matria Healthcare (each of these companies was acquired). He served on the Executive Committee of PhRMA, the pharmaceutical industry association, from 1997-1999. Mr. Yetter holds a B.A. in Biology from Wilkes University and an M.B.A from Bryant University.
Cris Arnou, MSE, MBA,
Board of Directors Member, Co-Founder and CEO
Cris Arnou is AgoneX Biopharmaceuticals Inc. Co-Founder and CEO. As a migraine sufferer for more than 35 years he is determined and committed to implementing the migraine treatment and prevention throughout the U.S. via existing medical offices.
In the past, Mr. Arnou has worked for two start-up companies and knows what it takes to build a successful, prosperous business. Additionally, Cris spent 10 years working at Ford Motor Company covering different aspects of product development, marketing and product launch.
Cris holds Bachelor and Master Degrees in Engineering from the University of Michigan, Ann Arbor and an MBA from Wayne State University in Detroit. He is a veteran of the U.S. Army.
Randy Jones, JD
Board of Directors Member, Chief Legal Officer and Secretary
Randy Jones is Chief Legal Officer and Secretary for AgoneX Biopharmaceuticals Inc. He is also Principal of Solutions Business Group, which he founded in 2009 as a business services firm dedicated to assisting for-profit and non-profit businesses achieve stretch goals, resolve difficult challenges and navigate periods of change or transition. Prior to founding Solutions Business Group, Mr. Jones spent more than 20 years working for global corporations in a wide range of industries including pharmaceuticals, biotech, energy and chemicals. His distinguished career encompasses a variety of roles including engineer, in-house legal counsel and senior executive in charge of legal, human resources, corporate compliance and ethics. Mr. Jones also spent 6 years as General Counsel of TalecrisBiotherapeutics, a company that reached a $4.4B market cap. Mr. Jones holds a Bachelor of Chemical Engineering from the University of Delaware and a Juris Doctor from the University of Virginia.